Clover Health Investments, Corp.
CLOVHealthcareNASDAQHealthcare Plans · Last scanned Sep 4, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of Sep 3
Clover Health Investments, Corp. The company carries a $2.26B market cap, placing it firmly in the mid-cap category. provides medicare advantage plans in the United States.
Market Cap
$2.26B
Beta
2.48
P/E (TTM)
—
P/E (Fwd)
28.37
EPS (TTM)
$-0.05
EPS (Fwd)
$0.15
ROE
-5.1%
ROA
-1.8%
Cash
$243.1M
Total Debt
$0
Free CF
$69.0M
52W Change
56.4%
Annual Financials
Cash vs Debt
Where CLOV stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CLOV finished 29.52% above its 150-day moving average ($3.32) and 37.82% above its 200-day moving average ($3.12). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CLOV overbought or oversold?
At the September 3, 2026 close, CLOV's RSI(14) was 41.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Clover Health Investments, Corp. reports $243.1M in cash and $0 in total debt. Annual free cash flow of $69.0M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -5.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $1.10B (2022) to $1.92B (2025), reflecting a 75% increase over the period.
A beta of 2.48 means CLOV is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. No single metric tells the full story. Reviewing CLOV's risk profile alongside its fundamentals and technical indicators provides a more complete picture.